You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t
SBC: AADI, LLC Topic: 102DESCRIPTION provided by applicant In it is estimated that there will be new bladder cancer cases in the United States resulting in deaths Most cases present with nonmuscle invasive bladder cancer NMIBC Intravesical bacillus Calmette Guerin BCG which elicits a nonspecific local immune response is considered the standard first line treatment However ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Whole Brain Nanoscale Preservation Imaging
SBC: Nectome Inc. Topic: 101Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users
SBC: AUTOMATE SCIENTIFIC, INC. Topic: NIDAAbstract E cigarettes (E-cigs) are increasingly popular worldwide, in particular, among youths. E-cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smoking. Mainstream and second-hand E-cig aerosols contain, in addition to nicotine, detectable levels of toxins including carcinogens and heavy metals such as formaldehyde, benzene, nitrosamines, cadmium a ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel therapy for Fragile X syndrome
SBC: Epigen Biosciences, Inc. Topic: 101PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Percutaneous Ultrasound-Guided Catheter for Organ and Vascular Access
SBC: PERCEPTIVE NAVIGATION LLC Topic: NHLBIDESCRIPTION provided by applicant Safe and reliable access to major blood vessels and internal organs will be beneficial to patients with cardiovascular disease and cancer An interventional catheter with forward viewing ultrasound imaging capability will be developed to enable image guided access to blood vessels and internal organs Phase experiments demonstrate feasibility of building a hi ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
A Novel, Microscale, Distributable Sensor Technology for Ionizing Radiation
SBC: CFD RESEARCH CORPORATION Topic: DTRA14B004Terrorist use of radioactive nuclear materials via nuclear and/or radiological dispersion devices (dirty bombs) is a serious threat. Therefore, it is crucial to detect proliferation of nuclear material. Critical challenges include: (a) high sensitivity detection of signature emissions from radioactive isotopes, and (b) cost-effectiveness for deployment of sensor networks across large storage facil ...
STTR Phase II 2019 Department of DefenseDefense Threat Reduction Agency -
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
SBC: ARIMA GENOMICS, INC. Topic: 172DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS
SBC: NOVORON BIOSCIENCE INC Topic: NINDS7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Selective inhibitors of Heme Transporters as Antiparasitic Agents
SBC: RAKTA THERAPEUTICS INC Topic: NIAIDDESCRIPTION provided by applicant Neglected Tropical Diseases NTD which include helminthiasis and leishmaniasis are a group of thirteen parasitic and bacterial infections that affect over billion people Although these are devastating diseases of global concern their neglected status relative to other health concerns has resulted in a limited arsenal of therapeutic compounds for their ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel monoclonal antibody for single dose treatment of acute CNS injury
SBC: Oncosynergy, Inc. Topic: 999PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health